Latest Global Markets News

Talius Group reports a robust December quarter with $4.4 million revenue, positive operating cash flow, and a strategic $2.5 million capital raise, positioning the company for strong growth in 2025 amid evolving aged care legislation.

EP&T Global delivered a positive net operating cash inflow of $0.4 million in the December 2024 quarter, supported by an 11% increase in customer receipts and a $1 million private placement to back expansion plans.

Imricor Medical Systems reports strong Q4 CY24 progress with successful FDA review, CE Mark submissions, and an 840% jump in consumables revenue, positioning the company for expanded global market penetration.

Alcoa Corporation reported robust fourth quarter and full year 2024 results, driven by higher alumina and aluminum prices, operational gains, and key strategic initiatives including the Alumina Limited acquisition.

Element 25 Limited has announced a 107% increase in Ore Reserves at its Butcherbird Manganese Project in Western Australia, now supporting an 18.3-year mine life at 1.1Mtpa production. This milestone underpins the company’s strategic expansion into battery-grade manganese supply for the EV market.

Emyria Limited announces key leadership shifts with Greg Hutchinson stepping up as Executive Chairman and Dr. Michael Winlo transitioning to Chief Scientific Officer, aiming to scale innovative mental health therapies amid growing demand.

Compumedics has locked in a pivotal five-year contract with Philips Australia, cementing Somfit as the leading device for pharmacy-based sleep testing and underpinning significant SaaS revenue growth through 2028.

Sovereign Metals Limited has released an Optimised Pre-Feasibility Study for its Kasiya Rutile-Graphite Project, reaffirming its position as a future global leader in critical minerals production with robust economics and operational improvements.

First Graphene Limited strengthens its financial footing with a UK R&D tax rebate and expands its global footprint through new distribution agreements in India and Brazil.

Recce Pharmaceuticals has successfully dosed all patients in its Phase II trial of RECCE® 327 topical gel for acute bacterial skin infections, showing encouraging preliminary efficacy and safety data. The company is preparing for pivotal Phase III trials in Australia and Indonesia, targeting a significant global market opportunity.

Wellnex Life has negotiated a delayed and reduced-cost payment arrangement for its Pain Away acquisition, aligning with its upcoming London Stock Exchange dual listing plans. The move supports the company’s growth momentum following record revenues from Pain Away.

Qoria Limited reports robust December quarter results for FY2025, driven by strong ARR growth, expanding global reach, and strategic AI innovations that promise to accelerate future growth.